Michel Velez, MD

Velez Michel
Breast Medical Oncology

Primary Office
1150 N 35th Avenue
Suite 170
Hollywood, FL 33021

Meet the Physician

Dr. Michel Velez is a board-certified hematologist/oncologist. Dr. Velez earned his medical degree from the Universidad del Norte, Colombia in 2000, after which he became involved in breast cancer research as a research associate at the Cancer Research Network and, subsequently, at Memorial Cancer Institute. He then went on to complete his internal medicine internship and residency at the University of Miami/Miller School of Medicine at JFK Medical Center and Veterans Affairs Medical Center Regional Campus, West Palm Beach. He completed his hematology-oncology fellowship at Jackson Memorial Hospital/University of Miami/Miller School of Medicine in 2014, where he served as chief fellow.

Dr. Velez has served as research associate in multiple clinical trials for the treatment of breast cancer, which ultimately have led to the approval of new therapies that have helped change the treatment of this disease.

  • Spanish


Professional organizations

  • American Society of Clinical Oncology, American medical association.

Recent publications

  • Azzi G, Velez M, Mathias-Machado MC: Isocitrate dehydrogenase mutations in chondrosarcoma: the crossroads between cellular metabolism and oncogenesis. Curr Opin Oncol. 2014 Jul;26(4):403-7.
  • Moh'd M. Khushman, Peter Joel Hosein, Michel Velez, et. al.: Updated survival analysis of patients (pts) with unresectable (UR) or borderline resectable (BR) locally advanced pancreatic adenocarcinoma (LAPC) treated with neoadjuvant FOLFIRINOX. J Clin Oncol 32, 2014 (suppl; abstr e15197).
  • Perez CA, Velez M, Raez LE, Santos ES: Overcoming the resistance to Crizotinib in patients with Non-Small Cell Lung Cancer harboring EML4/ALK translocation. Lung Cancer. 2014 May; 8 4(2): 110-115.
  • Belisario A. Arango1, Luis E. Aguirre1, Cesar A. Perez1, Michel Velez1,  Edgardo S. Santos2, Luis E. Raez3. Targeting angiogenesis in NSCLC cancer: A focus on current approaches and future developments. Future Medicine Jul 2013, Vol. 10, 4, 503-517.
  • Pimentel A, Velez M, Barahona L, Swords R, Lekakis L. New prospects for drug development – The hedgehog pathway revealed. Focus on hematologic malignancies. Future Oncol. 2013 May; 9(5): 681-97.
  • Velez M, Raez LE, Perez CA, Gomez JE, Mudad R, Vazquez AM, Santos ES. Abnormal elevation of erythrocyte mean corpuscular volume (MCV) in non-small cell lung cancer (NSLC) patients treated with maintenance pemtrexed-based chemotherapy. J Clin Oncol 30, 2012 (suppl; abstr e17564).
  • Velez M, Arango B, Raez LE, Santos ES: Mutations in tumorigenesis pathways driving personalized treatment in non-small cell lung cancer. J Clinic Experiment Pathol 2012, S5:002.
  • Perez CA, Arango BA, Velez M, Raez LE, Santos ES: Emergin role of multikinase inhibitors for refractory thyroid cancer. Biologics 2012; 6:257-65.
  • Velez M, Arango BA, Perez CA, Santos ES: Safety and efficacy of pemetrexed in maintenance therapy in non-small cell lung cancer. Clin Med Insights Oncol 2012; 6:117-24.
  • Escobar M, Velez M, Belalcazar A, Santos ES, Raez LE: The role of proteasome inhibition in non-small cell lung cancer,” J Biomed Biotechnol 2011; Epub 2011 May 4.
  • Velez M, Belalcazar A, Domingo G, Blaya M, Raez LE, Santos ES: Accelerated second-line or maintenance chemotherapy versus treatment at disease progression in NSCLC, Expert Rev Anticancer Ther 2010;10: 549-547.
  • Domingo G, Perez CA, Velez M, Cudris J, Raez LE, Santos ES: EGF receptor in lung cancer: A successful story of targeted therapy. Expert Rev Anticancer Ther 2010; 10:1577-1587.


  • Universidad Del Norte, 2000
  • University Of Miami-Jackson Memorial Hospital, 2014, Oncology and Hematology
  • American Board of Internal Medicine-Hematology
  • American Board of Internal Medicine-Internal Medicine
  • American Board of Internal Medicine-Oncology

Related Physicians